Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
35.33
+0.15 (0.43%)
May 7, 2025, 4:00 PM EDT - Market closed
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Xenon Pharmaceuticals stock have an average target of 56.22, with a low estimate of 49 and a high estimate of 67. The average target predicts an increase of 59.13% from the current stock price of 35.33.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xenon Pharmaceuticals stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 3 | 3 | 4 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 7 | 7 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Initiates $55 | Strong Buy | Initiates | $55 | +55.68% | May 7, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $60 → $52 | Strong Buy | Maintains | $60 → $52 | +47.18% | Apr 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +50.01% | Feb 24, 2025 |
| Deutsche Bank | Deutsche Bank | Strong Buy Initiates $67 | Strong Buy | Initiates | $67 | +89.64% | Feb 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +50.01% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
1.90M
Revenue Next Year
31.48M
from 1.90M
Increased by 1,553.36%
EPS This Year
-4.15
from -3.01
EPS Next Year
-4.60
from -4.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.4M | 169.3M | 318.5M | ||
| Avg | 1.9M | 31.5M | 147.4M | ||
| Low | n/a | n/a | 40.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 8,789.2% | 911.8% | ||
| Avg | - | 1,553.4% | 368.1% | ||
| Low | - | - | 29.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.36 | -3.85 | -1.22 | ||
| Avg | -4.15 | -4.60 | -4.01 | ||
| Low | -4.58 | -5.30 | -5.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.